Immune Clinical Trials

524 recruitingLast updated: May 13, 2026

There are 524 actively recruiting immune clinical trials across 55 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Early Phase 1, Phase 4. Top locations include Beijing, Beijing Municipality, China, Tianjin, Tianjin Municipality, China, Bethesda, Maryland, United States. Updated daily from ClinicalTrials.gov.


Immune Trials at a Glance

524 actively recruiting trials for immune are listed on ClinicalTrialsFinder across 6 cities in 55 countries. The largest study group is Phase 2 with 123 trials, with the heaviest enrollment activity in Beijing, Tianjin, and Bethesda. Lead sponsors running immune studies include Institute of Hematology & Blood Diseases Hospital, China, National Institute of Allergy and Infectious Diseases (NIAID), and Peking Union Medical College Hospital.

Treatments under study

About Immune Clinical Trials

Looking for clinical trials for Immune? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Immune trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Immune clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 524 trials

Recruiting

Deciphering the Genetic Architecture of Autoimmune Diseases

Autoimmune Diseases
National Human Genome Research Institute (NHGRI)300 enrolled2 locationsNCT06948110
Recruiting
Phase 2

Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

Autoimmune DiseaseProteinuriaGlomerular Disease+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)30 enrolled2 locationsNCT00977977
Recruiting
Phase 1Phase 2

Controlling Hyperactive Immunity With Long-lived Lymphocytes

Rheumatoid Arthritis (RA)Autoimmune Rheumatologic DiseaseDiffuse Cutaneous Systemic Sclerosis+1 more
Quell Therapeutics Limited16 enrolled6 locationsNCT07473154
Recruiting
Phase 2

A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)

Primary Immune Thrombocytopenia (ITP)Primary Evans Syndrome (ES)
Novartis Pharmaceuticals164 enrolled2 locationsNCT07421167
Recruiting
Early Phase 1

CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases

Relapsing or Refractory Multiple Sclerosis (MS)Myasthenia Gravis (MG)Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)+1 more
Tongji Hospital36 enrolled1 locationNCT07337785
Recruiting
Phase 3

A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Thrombocytopenia, Neonatal Alloimmune
Janssen Research & Development, LLC39 enrolled21 locationsNCT06449651
Recruiting
Phase 3

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Immune Thrombocytopenic Purpura (ITP)
Takeda171 enrolled112 locationsNCT06722235
Recruiting

Global Cardio Oncology Registry

Breast CancerCardiotoxicityCardiovascular Diseases+2 more
The Cleveland Clinic5,000 enrolled1 locationNCT05598879
Recruiting
Phase 3

A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Thrombocytopenia, Neonatal Alloimmune
Janssen Research & Development, LLC50 enrolled24 locationsNCT06533098
Recruiting
Phase 1

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

Neuromyelitis Optica Spectrum Disorder (NMOSD)Multiple Sclerosis (MS)Myasthenia Gravis (MG)+4 more
Tongji Hospital6 enrolled1 locationNCT07526493
Recruiting
Phase 3

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

ChemotherapyRadiotherapyImmune Checkpoint Inhibitor+1 more
Sun Yat-sen University380 enrolled3 locationsNCT05941741
Recruiting

Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)

PneumoniaInfectionsImmune System Diseases+2 more
National Institute of Allergy and Infectious Diseases (NIAID)600 enrolled1 locationNCT00006150
Recruiting

Studies of Disorders With Increased Susceptibility to Fungal Infections

Fungal infectionsPrimary Immune Deficiencies
National Institute of Allergy and Infectious Diseases (NIAID)850 enrolled1 locationNCT01222741
Recruiting
Phase 2

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

Immune Thrombocytopenia
Incyte Corporation56 enrolled40 locationsNCT07104565
Recruiting

Detection and Characterization of Infections and Infection Susceptibility

Immune Deficiencies
National Institute of Allergy and Infectious Diseases (NIAID)2,000 enrolled1 locationNCT00404560
Recruiting
Not Applicable

Mediterranean Diet Versus Western Diet on Fatigue in Autoimmune Hepatitis Patients

Autoimmune Hepatitis
Indiana University48 enrolled1 locationNCT06250309
Recruiting

Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRS

Myelodysplastic SyndromesAplastic AnemiaAutoimmune Hemolytic Anemia+1 more
Institute of Hematology & Blood Diseases Hospital, China323 enrolled1 locationNCT07578675
Recruiting

Pathophysiology of Inborn Immunodeficiencies

Primary Immune Deficiency Disorder
University of Zurich300 enrolled1 locationNCT03422614
Recruiting
Phase 2

Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)

Immune DysregulationPrimary Immune Regulatory DisorderChronic Granulomatous Disease+12 more
Paul Szabolcs25 enrolled1 locationNCT07284641
Recruiting
Phase 2

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

Primary immune thrombocytopenia
Pfizer91 enrolled16 locationsNCT05070845